
EVIDENCE BASED MEDICINE OF **ADRENALINE** FOR TREAMENT IN ACUTE BRONCHIOLITIS.

DR HUYEN TON NU THUY MY RESPIRATORY DEPARTMENT



PEDIATRACADEMY OF PEDIATRICS

Diagnosis and Management of Bronchiolitis Subcommittee on Diagnosis and Management of Bronchiolitis *Pediatrics* 2006;118;1774-1793 DOI: 10.1542/peds.2006-2223

2006: BRONCHIOLATORS IN BRONCHIOLIS

• **RECOMMENDATION 2B**

- Inhaled bronchodilators should be continued only if there is a documented positive clinical response.
- The AHRQ evidence report notes that nebulized Adrenaline has "some potential for being efficacious.
- The Cochrane: Use Adrenaline for inpatients and Outpatients

Management of Bronchiolitis in 2010

 TABLE 3
 Summary of Recent Evidence for Therapies Used for Bronchiolitis

| Therapy | Summary | Recommendation | | |
|-------------------------------------|---|--|--|--|
| Bronchodilators | No improvement in duration of illness or hospitalization ^{58,59} | No routine use | | |
| | May improve short-term clinical scores in a subset of children ⁵⁸ | Use only after proven benefit in a trial of therapy, if chosen as an option | | |
| Corticosteroids | No improvement in duration of illness or hospitalization ^{7,83} | No routine use | | |
| Leukotriene receptor antagonists | No improvement in duration of illness ^{67,75} | Not recommended | | |
| Nebulized hypertonic saline | May reduce length of inpatient hospitalization ⁷⁰ | None | | |

Evidence Based Guideline for The Management of bronchiolitis in Pediatrics 2010; 125; 342-349

ADRENALINE IN BRONCHIOLITIS 2011 WHAT'S NEW ?

Steroids and Bronchodilators for Acute Bronchiolitis in the first two years of life: Systematic Review And Meta-Analysis

The Cochrane library and The treatment of Bronchiolitis in 2011 British Medical journal: January – 27 – 2011 Published online: April – 6 - 2011

SYSTEMATIC REVIEW AND META - ANALYSIS


- 48 studies (4897 patients).
- RCTs of Children aged < 24 month.
- First Episode of Bronchiolitis with wheezing.
- Bronchodilator or steroid, alone or combined, with placebo or another intervention.
- Rate of admission for outpatients (day 1 and up to day 7) and length of stay for inpatients.

BRONCHODILATORS AND GLUCOCORTICOIDS FOR TREATMENT OUTPATIENTS IN ACUTE BRONCHIOLITIS.

The Cochrane library and The treatment of Bronchiolitis in 2011 British Medical journal: January – 27 – 2011 Published online: April – 6 - 2011

| | lo of studies lo of patient | | Risk ratio (95% CI) | l ² (%) |
|------------------------------------|--------------------------------|----------------|------------------------|--------------------|
| Admissions day 1 | | | | |
| Steroid v placebo | 8/1762 | + | 0.92 (0.78 to 1.08) | 0 |
| Steroid v adrenaline | 2/444 | | 1.12 (0.66 to 1.88) | 2 |
| Steroid v salbutamol | 1/45 | | 1.00 (0.21 to 4.86) | NA |
| Adrenaline v placebo | 4/920 | | 0.67 (0.50 to 0.89) | 0 |
| Adrenaline v salbutamol | 6/295 | | 0.65 (0.38 to 1.13) | 48 |
| Salbutamol or terbutaline v placeb | 0 4/196 | | 0.78 (0.53 to 1.14) | 0 |
| Ipratropium v placebo | 1/69 | | 1.56 (0.84 to 2.90) | NA |
| Adrenaline + steroid v placebo | 1/400 | | 0.65 (0.40 to 1.05) | NA |
| Salbutamol + steroid v placebo | 1/30 | | 0.67 (0.13 to 3.44) | NA |
| Salbutamol + steroid v adrenaline | 2/64 | | 5.00 (0.26 to 96.13) | NA |
| Admissions day 7 | | | | |
| Steroid v placebo | 5/1530 | - | 0.86 (0.70 to 1.06) | 31 |
| Steroid v adrenaline | 1/399 | | 1.08 (0.77 to 1.52) | NA |
| Adrenaline v placebo | 1/800 | | 0.78 (0.59 to 1.04) | 21 |
| Adrenaline v salbutamol | 1/63 | | 1.03 (0.66 to 1.60) | NA |
| Salbutamol or terbutaline v placeb | 0 2/259 | | 1.03 (0.34 to 3.10) | 0 |
| Adrenaline + steroid v placebo | 1/400 | | 0.65 (0.44 to 0.95) | NA |
| | 0 | .1 0.2 0.5 1 2 | 5 10 | |
| | F | avours A Favo | urs B | |

Results from meta-analysis of direct comparisons for admission rates from emergency department (day 1 and day 7) in outpatients.



Results of mixed treatment analysis for admissions at day 1.

OUTPATIENT OUTCOMES

| Outcome | Comparison | Number of subjects (studies) | Measure of effect (95% CI) | l ² | Quality of evidence (GRADE) |
|---------------------------------------|--|---------------------------------|---------------------------------------|----------------|--------------------------------|
| Hospitalization rate on day 1 | Glucocorticoid vs placebo | 1730 (8) | RR: 0.92 (0.78, 1.08) | 0% | High |
| | Epinephrinevsplacebo | 920 (4) | RR: 0.67 (0.50, 0.89) ^ª | 0% | Moderate |
| | Epinephrine and glucocorticoid vs placebo | 401 (1) | RR: 0.64 (0.40, 1.04) | | Low |
| Hospitalization rate within 7 days | Epinephrine vs bronchodilator | 295 (6) | RR: 0.65 (0.38, 1.13) | 48% | Moderate |
| | Glucocorticoid vs epinephrine | 444 (2) | RR: 1.12 (0.66, 1.88) | 2% | Moderate |
| | Glucocorticoid vs placebo | 1498 (5) | RR: 0.86 (0.70, 1.06) | 31% | Moderate |
| | Epinephrine vs placebo | 800 (1) | RR: 0.78 (0.59, 1.05) | 21% | Low |
| | Epinephrine and glucocorticoid <i>vs</i> placebo | 400 (1) | RR: 0.65 (0.44, 0.95) ^b | | Low |
| | Epinephrine vs bronchodilator | 63 (1) | RR: 1.03 (0.66, 1.60) | | Low |
| | Glucocorticoid vs epinephrine | 399 (1) | RR: 1.08 (0.77, 1.52) | - | Moderate |

OUTPATIENT OUTCOMES

| Clinical score at 60 minutes | Glucocorticoid vs placebo | 1006 (4) | SMD: - 0.04 (-0.16, 0.09) | 0% | High |
|----------------------------------|---|----------|--|-----|----------|
| | Epinephrine <i>vs</i> placebo | 900 (4) | SMD:-0.45 (-0.66, -0.23) [≗] | 40% | High |
| | Epinephrine and glucocorticoidvsplacebo | 399 (1) | SMD:-0.34 (-0.54, -0.14) ^b | | Moderate |
| | Epinephrine vs bronchodilator | 248 (6) | SMD: - 0.11 (-0.36, 0.14) | 0% | Moderate |
| | Glucocorticoid and bronchodilator vs placebo | 30 (1) | SMD: - 0.30 (-1.02, 0.42) | | Low |
| | Glucocorticoidvsepinephrine | 442 (2) | SMD: 0.31 (0.12, 0.50) ^ª | 0% | High |
| Clinical score at 120 minutes | Glucocorticoid vs placebo | 214 (3) | SMD: - 0.17 (-0.55, 0.21) | 43% | Moderate |
| | Glucocorticoid and bronchodilator vs placebo | 30 (1) | SMD: - 0.22 (-0.94, 0.50) | | Low |
| | Epinephrinevsplacebo | 30 (1) | SMD:-0.83 (-1.58, -0.08) [≗] | | Low |
| | Epinephrine vs bronchodilator | 207 (4) | SMD: - 0.09 (-0.37, 0.18) | 0% | Moderate |

RESULTS

- For outpatients with bronchiolitis, nebulized Adreanline decreased hospitalization rate on day one by 33%. (Grade: Moderate)
- Netbulized Adrenaline + glucocorticoids, there was a reduction of similar magnitude for hospitalization rate within seven days. (Grade: Low)
- Outpatients treated with epinephrine (High) or epinephrine and glucocorticoid combined both had significantly lower clinical scores at 60 minutes. (Grade: Moderate)

Authors' Conclusions

- For outpatients with bronchiolitis, nebulized Adrenaline can be effective in avoiding hospitalization.
- Systemic glucocorticoids such as dexamethasone cannot be recommended as a routine therapy given the current level of evidence and potential for adverse events.


The Cochrane library and The treatment of Bronchiolitis in 2011

BRONCHODILATORS AND GLUCOCORTICOIDS FOR TREATMENT IN-PATIENTS IN ACUTE BRONCHIOLITIS

The Cochrane library and The treatment of Bronchiolitis in 2011 British Medical journal: January – 27 – 2011 Published online: April – 6 - 2011

| | o of studie lo of patier | | | diffe 5% C | rence I) | | Mean difference (95% CI) | l ² (%) |
|------------------------------------|-----------------------------|-------|-------|---------------|-------------|-------|-----------------------------|--------------------|
| Length of stay (days) | 2012-24-0222-201 | | 7 | 1 | | | | |
| Steroid v placebo | 8/633 | | - | | | | -0.18 (-0.39 to 0.04) | 16 |
| Adrenaline v placebo | 2/292 | | | | | | -0.35 (-0.87 to 0.17) | 0 |
| Adrenaline v salbutamol | 4/261 | | | | | | 0.28 (-0.46 to -0.09) | 0 |
| Salbutamol or terbutaline v placeb | 0 6/346 | | | - | _ | | 0.11 (-0.26 to 0.48) | 0 |
| lpratropium v placebo | 2/148 | | | | - | | -0.04 (-0.53 to 0.45) | 26 |
| Salbutamol v ipratropium | 3/137 | | | - | - | | 0.13 (-0.33 to 0.58) | 0 |
| | | 1.0 | -0.5 | 0 | 0.5 | 1.0 | | |
| | | Favou | irs A | | Favo | urs B | | |

Results from meta-analysis of direct comparisons for length of stay in inpatients.



Results of mixed treatment analysis for length of stay.

INPATIENT OUTCOMES

| Outcome | Comparison | Number of subjects (studies) | Measure of effect (95% CI) | 1 ² | Quality of evidence (GRADE) |
|--|---|------------------------------------|--|----------------|-----------------------------------|
| Length of stay | Glucocorticoid vs placebo | 633 (8) | MD: - 0.18 (-0.39, 0.04) | 16% | High |
| | Bronchodilator vs placebo | 349 (6) | MD: 0.06 (-0.27, 0.39) | 0% | Moderate |
| | Epinephrine vs placebo | 292 (2) | MD: - 0.35 (-0.87, 0.17) | 0% | Moderate |
| | Epinephrinevsbronchodilator | 261 (4) | MD:-0.28 (-0.46, -0.09) ^a | 0% | Moderate |
| | 3% hypertonic salinevs0.9% saline | 282 (4) | MD:-1.16 | 0% | Moderate |
| | | | (-1.55, -0.77) ^b | | |
| | Chest physiotherapy vs standard care or other drainage/breathing technique | 172 (3) | MD: 0.07 (-0.58, 0.73) | 0% | Low |
| Re-admissions between 2 days and 4 months | Glucocorticoid vs placebo | 359 (3) | RR: 1.04 (0.12, 8.72) | 66% | Low |
| | Inhaled corticosteroid vs placebo | 309 (4) | RR: 1.15 (0.60, 2.22) | 45% | Moderate |
| | Epinephrine vs placebo | 192 (2) | RR: 0.29 (0.05, 1.86) | 0% | Low |
| Re-admissions between 3 months and 1 year | Inhaled corticosteroid vs placebo | 358 (5) | RR: 1.05 (0.63, 1.75) | 29% | Moderate |
| Clinical score at 60 | Epinephrinevsbronchodilator | 248 (4) | SMD:-0.79 (-1.45, -0.13) ^ª | 79% | Low |
| | Epinephrine vs placebo | 232 (2) | SMD: - 0.04 (-0.49, 0.40) | 46% | Moderate |
| Clinical score at 120 minutes | Epinephrinevsbronchodilator | 140 (1) | SMD:-0.52 (-0.86, -0.18) ^a | | Low |
| Clinical score at 1–3 days | Glucocorticoid vs placebo | 113 (4) | SMD: - 0.74 (-1.48, 0.01) | 70% | Low |

RESULTS

- For inpatients, nebulized Adrenaline versus bronchodilator decreased length of stay. Adrenaline decreased length of stay by seven hours.(Grade: Moderate)
- For inpatients, epinephrine versus bronchodilator led to a significantly lower clinical score at both 60 mins and 120 mins. (Grade: Low)

Authors' Conclusions

 For inpatients, nebulized Adrenaline and systemic and inhaled glucocorticoids cannot be recommended for inpatients given the weak level of evidence.

The Cochrane library and The treatment of Bronchiolitis in 2011

Side-effects of Netbulized Adrenaline

- Adrenaline inhalation is generally safe.
- Life-threatening Cardiac Arrhythmia after a Single Dose of Nebulized Adrenaline could be unpredictable in Pediatric Emergency Department. (Oxford Journals).

Oxford Journals: Journal of Tropical Pediatrics 2011


The safety of nebulization with 3 to 5 ml of adrenaline (1:1000)

- An evidence based review. (review article of "Jornal the pediatria").
- Evidence shows that nebulization with 3 to 5 ml of adrenaline (1:1000) is a safe therapy, with minor side-effects, for children with acute inflammatory airway obstruction.

Cost-effectiveness of Adrenaline and Dexamethasone in Bronchiolitis

- The Research group Pediatric Emergency Research Canada.
- This analysis is based on a double-blind RCT of 800 infants (Age: 6 w-12 m-M: 5 m). During 3 bronchiolitis seasons from 2004 through 2007.
- The most cost-effective treatment option
- The most effective in controlling symptoms and is associated with the least costs.

Cost-effectiveness acceptability curve.



Sumner A et al. Pediatrics 2010;126:623-631



CONCLUSION & DISCUSSION

- This review provides some important directions for clinical practice and future research.
- Adrenaline seems to be beneficial for short term outcomes among outpatients, including admission rates from the emergency department.
- Furthermore, adrenaline combined with dexamethasone showed longer term effects, reducing admission rates up to seven days after the emergency department visit.
- For inpatients, none of the interventions examined showed clear benefits for length of stay.

THANK YOU FOR ATTENTION!